• Gynecologic Cancer Treatment Center

    Selected published reports for 2009 – 2013

    Dana-Farber/Brigham and Women's Cancer Care

    2013:

    Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A Phase II trial of Sunitinib Malate in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma. Gynecol Oncol. 2013 Feb;128(2):215-20.

    Matulonis U, Lee, J, Lasonde B, Tew W, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Gastonguay V, Mackay HJ , Sidor CF, and Oza A. ENMD-2076, an Oral Inhibitor of Angiogenic and Proliferation Kinases, Has Activity in Recurrent, Platinum Resistant Ovarian Cancer. European J of Cancer 2013 Jan;49(1):121-31

    Wright AA, Stieglitz H, Kuperszatoch YM, et al... United States Acculturation and Cancer Patients' End-of-Life Care,” in press, PLOS One 2013.

    2012:

    Matulonis, Ursula, Pereira, Lauren; Liu, Joyce, Lee, Hang, Lee, Julie, Whalen, Christin, Campos, Susana, Atkinson, Tina, Hill, Margaret, Berlin, Suzanne T. Sequential metronomic bevacizumab and oral cyclophosphamide. Gyn Oncology 126(1):41-6, 2012.

    Stefan Bentink, Benjamin Haibe-Kains, Thomas Risch, Jian-Bing Fan, Michelle S. Hirsch, Kristina Holton, Renee Rubio, Craig April, Jing Chen, Eliza Wickham-Garcia, Joyce Liu, Aedin Culhane, Ronny Drapkin, John Quackenbush, Ursula A. Matulonis. Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer. PloS One published 13 Feb 2012 10.1371/journal.pone.0030269.

    Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol 125(2):510-1, 2012.

    Worley MJ Jr, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery. Gynecol Oncol. 2013 Jan 30.

    Horowitz N, Matulonis UA. New biologic agents for the treatment of gynecologic cancers. Hematol Oncol Clin North Am. 2012 Feb;26(1):133-56. doi: 10.1016/j.hoc.2011.11.002. Review.

    Ovarian cancer, version 3.2012 Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49.

    Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD; Australian Ovarian Cancer Study Group, Matulonis UA. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012 Oct 15;18(20):5806-15.

    Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander, Tamar Safra, Ignace Vergote, Mark Wickens, James Carmichael, Bella Kaufman. Phase II, open-label, randomized, multicenter study to compare the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and pegylated liposomal doxorubicin (PLD) in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology 30:372-379, 2012.

    Joyce Liu, MD, Mihaela Cristea, MD; Paul Frankel, MD; Susan L Neuhausen, PhD, Linda H Steele, Verena Engelstaedter, MD; Ursula Matulonis, MD; Sharon Sand, BA; Nadine Tung, Jeffery N Weitzel, Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and Survival, Cancer Genetics, 2012 Jan;205(1-2):34-41.

    Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Euan Macpherson, Claire Watkins, James Carmichael, Ursula Matulonis. Olaparib (AZD2281) maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer. NEJM. 2012 Apr 12;366(15):1382-92.

    Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. Phase II Trial of Erlotinib in Women with Squamous Cell Carcinoma of the vulva Gynecol Oncol. 2012 Oct;127(1):141-6.

    Ursula A. Matulonis, Sudarshan Sharma,Sharad Ghamande, Michael S. Gordon, Salvatore A. Del Prete, Isabelle Ray-Coquard, Elzbieta Kutarska, Hua Liu, Howard Fingert, Xiaofei Zhou, Hadi Danaee, and Russell J Schilder. Phase II Study of MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients With Platinum-Resistant or -Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. Gyn Oncology 2012 Oct;127(1):63-9.

    Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012;30(4):387-401.

    Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, Sabbatini P, Whalen C, Aghajanian CA, Zarwan C, Berlin S. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study. Cancer. 2012 May 1;118(9):2403.

    Townamchai K, Lee LJ, Poorvu PD, Damato AL, Viswanathan AN. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. Gynecol Oncol. 2012 Dec 21. doi:pii: S0090-8258(12)00974-2. 10.1016/j.ygyno.2012.12.026

    Poorvu PD, Sadow CA, Townamchai K, Damato AL, Viswanathan AN. Duodenal and Other Gastrointestinal Toxicity in Cervical and Endometrial Cancer Treated With Extended-Field Intensity Modulated Radiation Therapy to Paraaortic Lymph Nodes. Int J Radiat Oncol Biol Phys. 2012 Nov 20. doi:pii: S0360-3016(12)03654-1. 10.1016/j.ijrobp.2012.10.004.

    Lee LJ, Viswanathan AN. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1192-7. doi: 10.1016/j.ijrobp.2012.01.085. Epub 2012 May 15.

    2011:

    Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL. Epithelial ovarian cancer. J Natl Compr Canc Network. 2011 Jan;9(1):82-113.

    Matulonis UA. Bevacizumab and its use in epithelial ovarian cancer. Future Oncol. 2011 Feb 16.

    Lim K, Small W Jr, Portelance L, Creutzberg C, Jürgenliemk-Schulz IM, Mundt A, Mell LK, Mayr N, Viswanathan A, Jhingran A, Erickson B, De los Santos J, Gaffney D, Yashar C, Beriwal S, Wolfson A, Taylor A, Bosch W, El Naqa I, Fyles A; Gyn IMRT Consortium. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):348-55.

    Mak RH, Halasz LM, Tanaka CK, Ancukiewicz M, Schultz DJ, Russell AH, Viswanathan AN. Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Gynecol Oncol. 2011 Jan;120(1):101-7. Epub 2010 Oct 14.

    2010:

    Myers AP, Cantley LC. Targeting a common collaborator in cancer development. Sci Transl Med. 2010 Sep 8;2(48):48ps45.

    Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol. 2010:149362.

    Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR 3rd, Martin L, Morgan MA, Morgan RJ Jr, Mutch D, Remmenga SW, Reynolds RK, Small W Jr, Teng N, Valea FA. Cervical Cancer J Natl Compr Canc Netw. 2010 Dec;8(12):1388-416.

    Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. J Reprod Med. 2010 Jul-Aug;55(7-8):279-84.

    Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S116-22.

    Liu JF, Silver DP. Poly ADP-ribose polymerase inhibitors: science and current clinical development. Curr Opin Oncol. 2010 Nov;22(6):567-72.

    Holloway CL, Macklin EA, Cormack RA, Viswanathan AN. Should the organs at risk be contoured in vaginal cuff brachytherapy? Brachytherapy. 2010 Dec 28.

    Viswanathan AN, Creutzberg CL, Craighead P, McCormack M, Toita T, Narayan K, Reed N, Long H, Kim HJ, Marth C, Lindegaard JC, Cerrotta A, Small W Jr, Trimble E. International Brachytherapy Practice Patterns: A Survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys. 2010 Dec 22. Epub ahead of print.

    Folkins AK, Nevadunsky NS, Saleemuddin A, Jarboe EA, Muto MG, Feltmate CM, Crum CP, Hirsch MS. Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies. Mod Pathol. 2010 Aug;23(8):1073-9.

    Chang MC, Nevadunsky NS, Viswanathan AN, Crum CP, Feltmate CM. Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int J Gynecol Pathol. 2010 Jan;29(1):88-92.

    Duska LR, Garrett L, Henretta M, Ferriss JS, Lee L, Horowitz N. When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. 2010 Mar;116(3):374-7.

    Nagymanyoki Z, Kindelberger D, Clark R, Rodriguez N, Fulop V, Berkowitz RS. Age related cellular immune response against complete molar pregnancy.J Reprod Med. 2010 May-Jun;55(5-6):261-6.

    Cramer DW, O'Rourke DJ, Vitonis AF, Matulonis UA, Dijohnson DA, Sluss PM, Crum CP, Liu BC. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem. 2010 Dec;56(12):1889-92.

    Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010 Aug 28;376(9742):717-29

    Rodriguez N, Goldstein DP, Berkowitz RS. Treating gestational trophoblastic disease Expert Opin Pharmacother. 2010 Dec;11(18):3027-39.

    Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 1;28(1):154-9.

    Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, Kung AL, Hahn WC, Drapkin R, Livingston DM, Liu JF. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16;17(3):298-310.

    Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol. 2010 Feb;116(2):168-72.

    Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia. 2010 Feb;12(2):161-72.

    Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010 Mar;5(3):477-83.

    Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):104-9. Epub.

    S. Makhija, LC Amler, F. Ueland, M. Gold, D Dizon, V. Paton, M. Birkner, CY Lin, T Januario, A. Strauss, M. Sliwowski, U. Matulonis. Clinical activity of Gem plus pertuzumab in platinum resistant ovarian cancer, fallopian tube, or primary peritoneal cancer: low mRNA expression of the HER2 coreceptor HER 3 may be predictive of pertuzumab activity. J Clin Oncol. 2010 Mar 1;28(7):1215-23.

    Richard T. Penson, Don S. Dizon, Stephen A. Cannistra, Maria Roche, Carolyn N. Krasner, Suzanne T. Berlin, Neil S. Horowitz, Paul DiSilvestro, Ursula A. Matulonis, Hang Lee, Modjulie A. King, Susana M. Campos. Phase II Study of Carboplatin, Paclitaxel and Bevacizumab as First Line Chemotherapy for Advanced Müllerian Tumors. J Clin Oncol. 2010 Jan 1;28(1):154-9.

    Liu J, Matulonis UA. New advances in ovarian cancer. Oncology (Williston Park). Review 2010 Jul;24(8):721-8.

    Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010 Mar 1;28(7):1215-23.

    Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010 Mar;5(3):477-83.

    S.M. Campos, S.T. Berlin, L.M. Parker, W.Y Chen, C.A. Bunnell, T. Atkinson, J. Lee, U.A. Matulonis, C.N. Krasner, Michelle Hirsch and Lindsay Harris. Phase I trial of LIPOSOMAL DOXORUBICIN AND ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int Journal of Clinical Oncology 2010 Aug;15(4):390-8.

    Alice B. Kornblith, Kristina Mirabeau-Beale, Hang Lee, Annekathryn Goodman, Richard T. Penson, Lauren Pereira, and Ursula A. Matulonis. Long Term adjustment of survivors of ovarian cancer treated for advanced stage disease. J Psychosocial Oncology 2010 Sep;28(5):451-69.

    Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis UA, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof of concept trial. Lancet 2010 Jul24;376(9737):245-51.

    Wright AA, Keating NL, Balboni TA, Matulonis UA, Block SD, Prigerson HG. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol. 2010 Oct 10;28(29):4457-64

    Wright AA, Mack JW, Kritek PA, Balboni TA, Massaro AF, Matulonis UA, Block SD, Prigerson HG. Influence of patients' preferences and treatment site on cancer patients' end-of-life care. Cancer. 2010 Oct 1;116(19):4656-63.

    2009:

    Myers AP, Meyerhardt JA, Cantley LC. Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy? Clin Cancer Res. 2009 Nov 15;15(22):6748-50.

    Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1304-12. Review.

    Lee LJ, Sadow CA, Russell A, Viswanathan AN. Correlation of point B and lymph node dose in 3D-planned high-dose-rate cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):803-9. Epub 2009 Mar 13.

    Lin MC, Burkholder KA, Viswanathan AN, Neuberg D, Mutter GL. Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms. Cancer. 2009 May 15;115(10):2111-8.

    Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett. 2009 Aug 18;281(1):1-7.

    Matulonis, Ursula A., Karen J Krag, M.D..; Carolyn N Krasner, M.D.; Tina Atkinson, B.S. ; Neil S Horowitz, M.D.; Hang Lee, Ph.D.; Richard T Penson, M.D. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecol Oncol. 2009 Feb;112(2):394-9.

    Holloway CL, Racine ML, Cormack RA, O'Farrell DA, Viswanathan AN. Sigmoid dose using 3D imaging in cervical-cancer brachytherapy. Radiother Oncol. 2009 Nov;93(2):307-10.

    Berkowitz RS, Goldstein DP. Clinical practice. Molar pregnancy. N Engl J Med. 2009 Apr 16;360(16):1639-45.

    Viswanathan AN, Cormack R, Rawal B, Lee H. Increasing brachytherapy dose predicts survival for interstitial and tandem-based radiation for stage IIIB cervical cancer. Int J Gynecol Cancer. 2009 Nov;19(8):1402-6.

    Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH. Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 1;27(16):2686-91.

    Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009 Feb;9(1):39-44.

    Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, Cho KR, Copeland L, Crispens MA, Eifel PJ, Huh WK, Jaggernauth W, Kapp DS, Kavanagh JJ, Lurain JR 3rd, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Alvarez Secord A, Small W Jr, Teng N. Uterine Neoplasms. Clinical Practice Guidelines in Oncology. Journal of Natl Compr Canc Netw. 2009 May;7(5):498-531.

    Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska L, Pereira L, Bryan J, Matulonis UA Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug;114(2):353-9.

    Matulonis Ursula A, Suzanne Berlin, Percy Ivy, Karin Tyburski, Carolyn Krasner, Corrine Zarwan, Anna Berkenblit, Susana Campos, Neil Horowitz, Stephen A. Cannistra, Hang Lee, Julie Lee, Maria Roche, Margaret Hill, Christin Whalen, Laura Sullivan, Chau Tran, Benjamin D. Humphreys, and Richard T. Penson. AZD2171, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer Journal of Clinical Oncology 2009 Nov 20;27(33):5601-6.

    Hanstede MM, Wise LA, Stewart EA, Feldman S. The relation of annual surgeon case volume to clinical outcomes and resource utilization in abdominal hysterectomy. J Reprod Med. 2009 Apr;54(4):193-202.

    Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009 May;9(2):101-7.

    April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J, Cox D, Jones W, Rubio R, Holton K, Matulonis U, Quackenbush J, Fan JB. PLoS One. 2009 Dec 3;4(12):e8162.

    Liu JF, Hirsch MS, Lee H, Matulonis UA. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. 2009 Dec;115(3):401-406.

    Horowitz NS, Goldstein DP, Berkowitz RS. Management of gestational trophoblastic neoplasia. Semin Oncol. 2009 Apr;36(2):181-9.

    Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol. 2009 Feb;112(2):353-7.

    Lee LJ, Harris JR. Innovations in radiation therapy (RT) for breast cancer. Breast. 2009 Oct;18 Suppl 3:S103-11.

    Lee LJ, Sadow CA, Russell A, Viswanathan AN. Correlation of point B and lymph node dose in 3D-planned high-dose-rate cervical cancer brachytherapy Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):803-9.

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)
    • For children:
      888-733-4662 (888-PEDI-ONC)
    • Or complete the online form.